Amylyx Pharmaceuticals (AMLX) Scheduled to Post Quarterly Earnings on Thursday

Amylyx Pharmaceuticals (NASDAQ:AMLX) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, August 8th. Analysts expect Amylyx Pharmaceuticals to post earnings of ($0.38) per share for the quarter.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its earnings results on Friday, May 10th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.70). Amylyx Pharmaceuticals had a positive return on equity of 4.14% and a negative net margin of 17.86%. The business had revenue of $88.64 million for the quarter, compared to analyst estimates of $113.26 million. During the same period in the previous year, the company earned $0.02 earnings per share. On average, analysts expect Amylyx Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Amylyx Pharmaceuticals Price Performance

Amylyx Pharmaceuticals stock remained flat at $1.97 during trading on Tuesday. 865,842 shares of the company were exchanged, compared to its average volume of 2,338,038. The company has a fifty day moving average of $1.85 and a 200-day moving average of $5.65. Amylyx Pharmaceuticals has a 1 year low of $1.58 and a 1 year high of $22.51. The company has a market capitalization of $133.97 million, a price-to-earnings ratio of -1.86 and a beta of -0.63.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on AMLX shares. The Goldman Sachs Group raised their price target on shares of Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the company a “neutral” rating in a research note on Friday, July 12th. Mizuho decreased their target price on Amylyx Pharmaceuticals from $4.00 to $3.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Amylyx Pharmaceuticals in a research note on Wednesday, July 10th. Six research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $17.60.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.